Cellumed셀루메드
049180 · KOSDAQ · ₩049180 · 셀루메드
₩1,009 ₩0 (0.00%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 10.5% | 4.7% | 7.3% | 5.9% | 11.2% | 14.4% |
| Operating margin | 0.7% | −3.7% | −5.3% | −10.9% | −2.2% | 4.7% |
| Net margin | 2.2% | −1.6% | −24.4% | −39.0% | −4.6% | 8.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −14.5% | +8.6% | +35.1% | −21.7% | +22.2% | — |
| Operating income growth | +115.4% | +24.9% | +34.7% | −283.3% | −157.5% | — |
| Net income growth | +219.7% | +92.9% | +15.4% | −569.5% | −168.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 15.8% | −26.1% | −202.0% | −97.6% | −10.9% | 17.0% |
| Return on assets | 4.5% | −3.3% | −46.6% | −47.5% | −5.7% | 8.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 182.9% | 625.9% | 675.0% | 188.8% | 69.2% | 96.5% |
| Net debt to equity | 17.1% | 65.2% | −9.4% | 36.1% | 0.9% | −16.2% |
| Current ratio | 133.4% | 89.7% | 89.5% | 126.8% | 193.4% | 171.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Cellumed / 셀루메드 / 049180 / KRX:049180
Source: KRX statistical information